caa a22 4500 469074078 CHVBK 20180323132930.0 cr unu---uuuuu 170328e19920301xx s 000 0 eng 10.1007/BF01741861 doi (NATIONALLICENCE)springer-10.1007/BF01741861 Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines [Elektronische Daten] [Zulma Gazit, David Weiss, Daniel Shouval, Michal Yechezkeli, Volker Schirrmacher, Michael Notter, Jürgen Walter, Eli Kedar] Summary: The antitumor effects of chemotherapy, recombinant human interleukin-2 (IL-2), recombinant human interferon α A/D (IFNα), allogeneic human lymphokine-activated killer (LAK) cells, and antitumor monoclonal antibody (mAb), administered alone and in various combinations, were tested in athymic nude mice carrying human tumor xenografts. Treatment began 6-18 days after i.v. or i.p. inoculation of colorectal carcinoma or melanoma cell lines, when macroscopic growths were evident. Chemotherapy consisted of two or three courses of 5-fluorouracil (5-FU) or dacarbazine. IL-2 and/or IFNα were administered three to five times weekly for 1-3 weeks, usually starting 2-5 days after chemotherapy. Human LAK cells were infused once or twice weekly for 2 or 3 weeks concurrently with IL-2. In some experiments, murine anticolorectal carcinoma mAb (SF25) was administered. In both tumor systems, chemotherapy alone or immunotherapy alone (IL-2, IL-2 + LAK cells, IFNα, IL-2 + IFNα ± LAK cells) had little or no therapeutic effects. Additive effects were obtained by combining chemotherapy with IL-2 and LAK cells or with IL-2 and IFNα. In the majority of the experiments, the most effective combination was chemotherapy + IL-2 + IFNα + LAK cells. Treatment with mAb was beneficial in the colorectal carcinoma system when combined with 5-FU + IL-2 or 5-FU + IL-2 + IFNα. Homing experiments with radiolabeled human and mouse LAK cells injected i.v. showed increased early accumulation in the liver and lungs, whereas freshly explanted mouse splenocytes localized mostly in the spleen and liver. The tissue distribution pattern of human LAK cells was similar in normal and tumor-bearing mice (with lung metastases). These findings suggest that combination of chemotherapy with cytokines and LAK cells can be partially effective for advanced solid human tumors even in the absence of the host's T-cell immune response. Preliminary experiments showed that tumor-specific, anti-melanoma T-cell clones were effective in local (s.c.) tumor growth inhibition (Winn assay) following coinjection with the autologous tumor cells. Springer-Verlag, 1992 Human tumor xenografts nationallicence Chemo-adoptive immunotherapy nationallicence Cytokines nationallicence T cells nationallicence Gazit Zulma The Lautenberg Center for General and Tumor Immunology, The Hebrew University — Hadassah Medical School, 91 010, Jerusalem, Israel aut Weiss David The Lautenberg Center for General and Tumor Immunology, The Hebrew University — Hadassah Medical School, 91 010, Jerusalem, Israel aut Shouval Daniel The Liver Unit, Hadassah Medical Center, Jerusalem, Israel aut Yechezkeli Michal The Lautenberg Center for General and Tumor Immunology, The Hebrew University — Hadassah Medical School, 91 010, Jerusalem, Israel aut Schirrmacher Volker The Institute for Immunology and Genetics, DKFZ, Heidelberg, Germany aut Notter Michael The Institute for Immunology and Genetics, DKFZ, Heidelberg, Germany aut Walter Jürgen The Institute for Immunology and Genetics, DKFZ, Heidelberg, Germany aut Kedar Eli The Lautenberg Center for General and Tumor Immunology, The Hebrew University — Hadassah Medical School, 91 010, Jerusalem, Israel aut Cancer Immunology, Immunotherapy Springer-Verlag 35/2(1992-03-01), 135-144 0340-7004 35:2<135 1992 35 262 https://doi.org/10.1007/BF01741861 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741861 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Gazit Zulma The Lautenberg Center for General and Tumor Immunology, The Hebrew University — Hadassah Medical School, 91 010, Jerusalem, Israel aut NATIONALLICENCE 700 1- Weiss David The Lautenberg Center for General and Tumor Immunology, The Hebrew University — Hadassah Medical School, 91 010, Jerusalem, Israel aut NATIONALLICENCE 700 1- Shouval Daniel The Liver Unit, Hadassah Medical Center, Jerusalem, Israel aut NATIONALLICENCE 700 1- Yechezkeli Michal The Lautenberg Center for General and Tumor Immunology, The Hebrew University — Hadassah Medical School, 91 010, Jerusalem, Israel aut NATIONALLICENCE 700 1- Schirrmacher Volker The Institute for Immunology and Genetics, DKFZ, Heidelberg, Germany aut NATIONALLICENCE 700 1- Notter Michael The Institute for Immunology and Genetics, DKFZ, Heidelberg, Germany aut NATIONALLICENCE 700 1- Walter Jürgen The Institute for Immunology and Genetics, DKFZ, Heidelberg, Germany aut NATIONALLICENCE 700 1- Kedar Eli The Lautenberg Center for General and Tumor Immunology, The Hebrew University — Hadassah Medical School, 91 010, Jerusalem, Israel aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/2(1992-03-01), 135-144 0340-7004 35:2<135 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer